coli strain HB101 and the bald fim2-negative

K pneumonia

coli strain HB101 and the bald fim2-negative

K. pneumoniae C3091∆fim∆mrk mutant was pursued. Yet again evidence of a fim2-associated phenotype was elusive and only apparent in HB101 and then too only when crystal violet-staining data were buy LEE011 standardised for total pre-wash cell numbers. Attempts to alleviate the observed growth retardation associated with over-expression of fim2 in a HB101 background by reducing incubation temperature to 30°C and by providing rare tRNAs in trans were unsuccessful. Furthermore, the observed growth retardation was highly reproducible even when newly generated HB101 strains possessing independently-constructed pFim2-Ptrc plasmids were used instead (van Aartsen and Rajakumar, unpublished data). Thus, it would appear that over-expression SN-38 cell line of fim2 in HB101 was specifically responsible for this phenotype, though no comparable effect occurred with over-expression of fim. The presence of fim2 in more than one species and its global spread suggests that this horizontally acquired locus has been maintained within a subset of the Klebsiella population due to positive selection. Hence, although the role fim2 remains elusive, given the glimpses of functionality hinted at by our data and the evolutionary survival

of this multi-gene entity, we hypothesize that putative Fim2 contributes to pathogenesis of infection and/or Akt inhibitor ic50 environmental persistence, at least under highly specific conditions. Conclusions In conclusion, we have described Etomidate the KpGI-5 island which possessed a novel γ1-type CU operon called fim2. Although fim2 was shown to be expressed at an mRNA level and its function was investigated using three distinct murine infection models, tissue culture experiments and biofilm assays, no obvious in vitro or in vivo role for the fim2 locus was identified, although there were subtle hints of involvement in urovirulence and in bacterial

dissemination from the respiratory tract. Nevertheless, as fim2 was found in approximately 13% of Klebsiella spp. isolates examined, we propose that fim2 has the potential to contribute beneficially to its host Klebsiella strains at least under specific conditions. Methods Bacterial strains, plasmids, and growth media Bacterial strains and plasmids used in this study are described in Table 3. K. pneumoniae KR116 is a human blood stream infection isolate obtained from the University Hospitals of Leicester. Unless otherwise specified, strains were routinely cultured at 37°C in LB medium supplemented with 50 μg/ml apramycin, 250 μg/ml ampicillin, 30 μg/ml chloramphenicol, 50 μg/ml kanamycin and/or 15 μg/ml tetracycline for K. pneumoniae, and 100 μg/ml ampicillin, 12.5 μg/ml chloramphenicol, 50 μg/ml kanamycin and/or 10 μg/ml tetracycline for E. coli.

Drugs Future 23:702–706CrossRef Mazerska Z, Gorlewska K, Kraciuk

Drugs Future 23:702–706CrossRef Mazerska Z, Gorlewska K, Kraciuk A, Konopa J (1999) The relevance of enzymatic oxidation by horseradish peroxidase to antitumour potency of imidazoacridinone derivatives. Chem Biol Interact 115:1–22CrossRef Mazerska Z, Sowiński P, Konopa J (2003) Molecular mechanism of the enzymatic oxidation investigated for imidazoacridinone antitumor

drug, C-1311. Biochem Pharmacol 66:1727–1736PubMedCrossRef Mazerski J, Muchniewicz K (2000) The intercalation of imidazoacridinones into DNA induces this website conformational changes in their side chain. Acta Biochim Pol 47:65–78PubMed Put R, Daszykowski M, Bączek T, Vander Heyden Y (2006) Retention prediction of peptides based on uninformative variable elimination by partial least

squares. J Proteome Res 5:1618–1625PubMedCrossRef Składanowski A, Konopa J (2000) Mitoxantrone and ametantrone induce interstrand cross-links in DNA of tumour cells. Br J Cancer 82:1300–1304PubMedCrossRef Składanowski A, Plisov SY, Konopa J, Larsen AK (1996) Inhibition of DNA topoisomerase Wortmannin II by imidazoacridinones, new antineoplastic agents with strong activity against solid tumor. Mol Pharmacol 49:772–780PubMed Składanowski A, Larsen AK, Konopa J, Lemke K (1999) Inhibition of DNA topoisomerase II by antitumor triazoloacridinones in vitro and in tumor cells. Proc Am Assoc Cancer Res 40:681 Skwarska A, Augustin E, Konopa J (2007) Sequential induction of mitotic catastrophe followed by apoptosis in human leukemia MOLT4 cells by imidazoacridinone C-1311. Apoptosis 12:2245–2257PubMedCrossRef Todeschini R, Consonni V, Mannhold R, Kubinyi H, Timmerman H (2000) Handbook of molecular descriptors. Wiley-VCH, WeinheimCrossRef Wesierska-Gadek J, Schloffer D, Gueorguieva M, Uhl M, Skladanowski A (2004) Increased susceptibility of poly(ADP-ribose) polymerase-1 knockout cells to antitumor triazoloacridone

C-1305 is associated with permanent G2 cell cycle arrest. Cancer Res 64:4487–4497PubMedCrossRef Zaffaroni N, De Marco C, Villa R, Riboldi S, Daidone MG, Double JA (2001) Cell growth inhibition, G2M cell cycle arrest and apoptosis induced by the imidazoacridinone C1311 in human tumour cell lines. Eur J Cancer 37:1953–1962PubMedCrossRef”
“Introduction Ergoloid The carbon–carbon triple bond is one of the most important selleck products functional groups in organic chemistry and pharmacology. The structure activity relationship studies suggest that introduction of alkyne motif may significantly modify the chemical, physical, and biological properties of acetylenic compounds (Ben-Zvi and Danon, 1994). Among a large group of synthetic and natural acetylenic compounds the quinolines possessing an alkynyl moieties are of particular interest as many of them display important activities, namely antimicrobiological, anticancer, antiprotozoal, and antiretroviral (Fuita et al., 1998; Fakhfakh et al., 2003; Abele et al., 2002).

7 Children and adolescents should only consider use

of E

7. Children and adolescents should only consider use

of ED or ES with parental approval after consideration of the amount of carbohydrate, caffeine, and other nutrients contained in the ED or ES and a thorough understanding of the potential side effects.   8. Indiscriminant use of ED or ES, especially if more than one serving per day is consumed, may lead to adverse events and harmful side effects.   9. Diabetics and individuals with pre-existing cardiovascular, metabolic, hepatorenal, and neurologic disease who are taking medications that may be affected by high glycemic load foods, caffeine, and/or other p38 MAPK signaling stimulants should avoid use of ED and/or ES unless approved by their physician.   References 1. Froiland K, Koszewski W, Hingst J, Kopecky L: Nutritional VS-4718 solubility dmso supplement use among college athletes and their sources of information. Int J Sport Nutr Exerc Metab 2004, 14:104–120.PubMed 2. Hoffman : Caffeine and Energy Drinks. Strength Cond J 2010, 32:15–20.CrossRef 3. Hoffman JR, Faigenbaum AD, Ratamess NA, Ross

R, Kang J, Tenenbaum G: Nutritional supplementation and anabolic steroid use in adolescents. Med Sci Sports Exerc 2008, 40:15–24.PubMed 4. Petroczi A, Naughton DP, Pearce G, Bailey R, Bloodworth A, McNamee M: Nutritional supplement use by elite young UK athletes: fallacies of advice regarding efficacy. J Int Soc Sports Nutr 2008, here PubMedCrossRef 5. Wolk BJ, Ganetsky M, Babu KM: Toxicity of energy drinks. Curr Opin Pediatr 2012, 24:243–251.PubMedCrossRef 6. Kerksick C, Harvey T, Stout J, Campbell B, Wilborn C, Kreider

R, Kalman D, Ziegenfuss T, Lopez H, Landis J, et al.: International Society of Sports Nutrition 17-DMAG (Alvespimycin) HCl position stand: nutrient timing. J Int Soc Sports Nutr 2008, 5:17.PubMedCrossRef 7. Goldstein ER, Ziegenfuss T, Kalman D, Kreider R, Campbell B, Wilborn C, Taylor L, Willoughby D, Stout J, Graves BS, et al.: International society of sports nutrition position stand: caffeine and performance. J Int Soc Sports Nutr 2010, 7:5.PubMedCrossRef 8. Bonati M, Latini R, Galletti F, Young JF, Tognoni G, Garattini S: Caffeine disposition after oral doses. Clin Pharmacol Ther 1982, 32:98–106.PubMedCrossRef 9. Graham TE, Hibbert E, Sathasivam P: Metabolic and exercise endurance effects of coffee and caffeine ingestion. J Appl Physiol 1998, 85:883–889.PubMed 10. McLellan TM, Bell DG: The impact of prior coffee consumption on the subsequent ergogenic effect of anhydrous caffeine. Int J Sport Nutr Exerc Metab 2004, 14:698–708.PubMed 11. Kovacs EM, Stegen J, Brouns F: Effect of caffeinated drinks on substrate metabolism, caffeine excretion, and performance. J Appl Physiol 1998, 85:709–715.PubMed 12. Oka H, Suzuki S, Suzuki H, Oda T: Increased urinary excretion of L-xylulose in patients with liver cirrhosis. Clin Chim Acta 1976, 67:131–136.PubMedCrossRef 13.

and other bacteria The abbreviations correspond to following spe

and other bacteria. The abbreviations correspond to following species with accession number(s) in parentheses. Ye1A: Y. enterocolitica bioserovar

1A/O:6,30 (DQ350880); YeO8: Y. enterocolitica bioserovar 1B/O:8 (L24101, AM286415); YeO3: Y. enterocolitica bioserovar 4/O:3 (Z18865); Yers included Y. aldovae (AY363680), Y. bercovieri (AY363681), Y. frederiksenii (AY363682), Y. selleck chemical intermedia (AY363683), Y. kristensenii (AY363684), Y. mollaretii (AY363685), Y. rohdei (AY363686); Yps: Y. pseudotuberculosis Entospletinib molecular weight (U40842; CP000720; CP000950; BX936398); Ype: Y. pestis (CP000901, CP000308, AL590842, AE017042, CP000305, CP000668, AF095636); Pl: Photorhabdus luminescens (BX571866); Ei: Edwardsiella ictaluri (AY607844); Ka: Klebsiella aerogenes

(M36068) % identity is indicated in bold 0 indicates that the intergenic CHIR98014 mw region had overlapping stop and start codons *ureB gene size was 435 bp (Y. aldovae, Y. bercovieri, Y. intermedia, and Y. mollaretii), 441 bp (Y. rohdei), 468 bp (Y. frederiksenii) and 495 bp (Y. kristensenii); ureBC intergenic region of 201-202 bp was present in Y. aldovae and Y. intermedia The comparison of Y. enterocolitica biovar 1A ure genes Osimertinib in vivo and the deduced amino acid sequences with that of Yersinia spp. and other bacteria are given in Tables 2 and 3 respectively. Besides Yersinia species, the homologies of ure genes (upto 76% identity) and their deduced amino acid sequences (upto 86% identity and 95% similarity) were significant with ureases from Photorhabdus luminescens and Edwardsiella ictaluri. The UreA, UreC and UreG proteins were most conserved among Yersinia spp. The estimated molecular weights, in Da,

of the protein subunits were 11,048 (UreA), 15,854 (UreB), 61,026 (UreC), 25,507 (UreE), 25,040 (UreF), 24,181 (UreG) and 36,592 (UreD) (Table 3). Table 3 Urease structural and accessory proteins of Y. enterocolitica biovar 1A (Ye 1A).   Gene Gene product (aa) Mol. mass (Da)* pI* % identity/% similarity           YeO8 YeO3 Yers Yps Ype Pl Ei Ka Structural subunits                         UreA ureA 100 11,048 5.29 99-100 100 97-100/100 100 100 79/95 86/95 60/82 UreB ureB 144 15,854 9.06 84-85/85-86 85/86 84-99/85-99 86-94/88-97 78-94/79-97 60/72 61/73 36/47 UreC ureC 572 61,026 5.64 99/100 95/97 97-99/99-100 97/99 93-97/95-99 83/91 86/94 58/73 Accessory proteins                         UreE ureE 228 25,507 6.

0) † 34 (6 6) TOTAL: 76 (3 4) 35 (2 6) 192 (19 6) † 82 (12 2) 173

0) † 34 (6.6) TOTAL: 76 (3.4) 35 (2.6) 192 (19.6) † 82 (12.2) 173 (17.9) 104 (20.2) Patients were grouped into those who received cetuximab, either alone or in combination with other therapeutics, and controls (those who did not receive cetuximab). † p < 0.05 compared to control group. Discussion Overall, cetuximab seems to increase the incidence of adverse pulmonary reactions compared Linsitinib datasheet to controls, although the absolute

difference between groups is low (<2%). The severity of the pulmonary complications was not well described in most of the included studies, but did not increase mortality rates. To the contrary, if survival benefits were not demonstrated, almost universally, there was an increase in progression free survival or stability of malignancy in these

trials. To this point, the difference between statistical significance and clinical significance should also be examined in relation to the pulmonary reactions. For all clinical trials except NSCLC, the differences in pulmonary adverse events between those treated with and without cetuximab are small. Dyspnea and cough, though increased in the cetuximab groups, did not appear to limit the therapeutic course. The observation of increased pulmonary adverse events in patients with NSCLC when compared to controls was striking. Again, most of the adverse reactions in these patients were dyspnea or check details respiratory insufficiency, and were not noted to be treatment limiting. Although the mechanism for increased symptoms in patients with NSCLC is not well defined, it is not surprising that those with a site Cell Cycle inhibitor of action in the lung would suffer from exuberant local effects. Pneumonitis was seen in most patients (71%) treated with cetuximab in combination with radiation therapy for NSCLC, although there was no control group in this study for comparison [56]. These patients had Methocarbamol advanced disease and were treated with a radiation dose of 64Gy to the lungs, which is well above the threshold for pneumonitis with radiation alone[61] As expected, treatment of head/neck cancers in these trials had high overall rates

of pulmonary adverse events, although there were no significant differences between those who received cetuximab and those who did not. Severe adverse reactions were not common in clinical trials using cetuximab. Interstitial lung disease, cited as a rare complication in the medication’s package insert, was not described in the clinical trials included in this review with the exception of a case report of two post-lung transplantation patients treated with cetuximab for cutaneous malignancy. Obviously, there are likely confounding factors which may have predisposed this select population to the development of diffuse alveolar damage. For those described in the cetuximab package insert, interstitial lung disease was present before the institution of cetuximab therapy for malignancy.

Progr Cryst Growth Charact Mater 1998, 37:47 CrossRef 2 Singh NB

Progr Cryst Growth Charact Mater 1998, 37:47.CrossRef 2. Singh NB, Suhre DR, Rosch W, Meyer R, Marable M, Fernelius NC, Hopkins FK, Zelmon DE, Narayanan R: Modified GaSe crystals for mid-IR applications. J Cryst Growth 1999, 198:588.CrossRef

3. Fludarabine Allakhverdiev KR, Yetis MÖ, Özbek S, Baykara TK, Salaev EY: Effective nonlinear GaSe crystal. Optical properties and applications. Laser Phys 2009, 19:1092.CrossRef 4. Mandal KC, Kang SH, Choi M, Chen J, Zhang X-C, Schleicher JM, Schmuttenmaer CA, Fernelius selleck products NC: III–VI chalcogenide semiconductor crystals for broadband tunable THz sources and sensors. IEEE J Sel Topics Quant Electr 2008, 14:284.CrossRef 5. Rudolph R, Pettenkofer C, Bostwick AA, Adams JA, Ohuchi F, Olmstead MA, Jaeckel B, Klein A, Jaegermann W: Thiazovivin manufacturer Electronic structure of the Si(111): GaSe van der Waals-like surface termination. New J Phys 2005, 7:108.CrossRef 6. Adams JA, Bostwick AA, Ohuchi FS, Olmstead MA: Chemical passivity of III-VI bilayer terminated Si (111). Appl Phys Lett 2005, 87:171906.CrossRef 7. Fritsche R, Wisotzki E, Thißen A, Islam ABMO, Klein A, Jaegermann W, Rudolph R, Tonti D, Pettenkofer C:

Preparation of a Si(111): GaSe van der Waals surface termination by selenization of a monolayer Ga on Si(111). Surf Sci 2002, 515:296.CrossRef 8. Late DJ, Liu B, Ramakrishna Matte HSS, Rao CNR, Dravid VP: Rapid characterization of ultrathin layers of chalcogenides on SiO 2 /Si substrates. Adv Funct Mater 1894, 2012:22. 9. Hu PA, Wen Z, Wang L, Tan P, Xiao K: Synthesis of few-layer GaSe nanosheets for high performance photodetectors. ACS Nano 2012, 6:5988.CrossRef 10. Gautam UK, Vivekchand SRC, Govindaraj A, Kulkarni GU, Selvi NR, Rao CNR: Generation of onions and nanotubes of GaS and GaSe through laser and thermally induced exfoliation. J Amer Chem Soc 2005, 127:3659.CrossRef 11. Côté M, Cohen ML, Chadi DJ: Theoretical study of the structural and electronic properties of GaSe nanotubes. Phys Rev B 1998, 58:R4277.CrossRef

12. Chikan V, Kelley DF: Synthesis of highly luminescent GaSe nanoparticles. NanoLett 2002, 2:1015.CrossRef 13. Shao J, Mirafzal H, Petker JR, Cosio JLS, Kelley DF, Ye T: Nanoscale organization of GaSe quantum dots on a gold surface. J Phys Chem C 2009, 113:19102.CrossRef 14. Balitskii OA, Borowiak-Palen E, Konicki W: Synthesis and characterization of Reverse transcriptase colloidal gallium selenide nanowires. Cryst Res Technol 2011, 46:417.CrossRef 15. Allakhverdiev K, Hagen J, Salaeva Z: On a possibility to form small crystallites of layered gallium selenide via ultrasonic treatment. Phys Stat Sol 1997, 163:121.CrossRef 16. Rybkovskiy DV, Arutyunyan NR, Orekhov AS, Gromchenko IA, Vorobiev IV, Osadchy AV, Salaev EY, Baykara TK, Allakhverdiev KR, Obraztsova ED: Size-induced effects in gallium selenide electronic structure: the influence of interlayer interactions. Phys Rev B 2011, 84:085314.CrossRef 17. Scholes GD: Two dimensions are brighter. Nature Mater 2011, 10:906.CrossRef 18.

Sequence analysis was performed using the START2 software package

Sequence analysis was performed using the START2 software package [48] where the number of nucleotide differences and ratio of nonsynonymous to synonymous substitutions (dN /dS ) were calculated. MEGA5 was used to construct a phylogenetic tree based on the concatenated sequences (adk;ccpA;recF;rpoB;spo0A;sucC) by the NJ-method with branch lengths estimated by the Maximum Composite Likelihood method [47, 49]. Minimum spanning tree (MST) was generated

in BioNumerics v.6.6 (Applied Maths NV) using the categorical coefficient. Index of associaton (IA) To test the null hypothesis of linkage equilibrium Selleck RG-7388 (alleles are independent) between the alleles of the six MSLT loci, IA values were calculated in START2 by the classical (Maynard Smith) and the standardized (Haubold) method [48]. The test was repeated on a dataset containing only one isolate per ST in order to avoid the risk of a bias toward a clonal population for strains with the same epidemiological history (e.g. the abortifacient strains) [35]. Results and discussion MLST analysis

The percentage of variable sites at each locus ranged from 3.6 (sucC) to 7.5 (adk) (Table  2) which is low compared to data obtained for the B. cereus group (several species) but comparable to MLST data for Clostridium septicum[32, 35]. To our knowledge there are no similar data available for other species within the B. subtilis group which makes relevant comparison difficult. The discriminatory Adavosertib solubility dmso ability of the different loci, measured as number of alleles, varied from four (adk) to eleven (ccpA) (Table  3). Despite GDC-0068 manufacturer having the lowest allele number, adk represented the least conserved locus, containing the highest frequency of variable sites and also had the highest dN/dS nonsynonymous (change of amino acid) to synonymous (no change of amino acid) substitution ratio. In contrast, all of the 14 substitutions

in recF and 13 substitutions in rpoB were synonymous still providing five different alleles (Table  2 and 3). However, the dN/dS ratios of all six loci were close to zero, and quite low compared to other studies, indicating that they are all under stabilizing selection [35, 39, 50]. Among the 53 B. licheniformis strains included ID-8 in this study 27 different sequence types (STs) were identified (Figure  1). 19 STs were represented by only one strain. These strains clustered into two main groups, designated A and B (Figure  1). The strict group division was also consistent within every single locus, as observed by the Neighbor-Joining (NJ) cluster analysis for each individual locus (Additional file 1). Our results corresponded well with previous findings of two different lineages within B. licheniformis[28]. The majority of our strains (74%) including the type strain ATCC14580 clustered into group B. These strains seemed to be more closely related to each other than the strains in group A.

Peeters, unpublished data smmgag smmgagF1 (5′-TGGGAGATGGGCGCGAGAA

Peeters, unpublished data smmgag smmgagF1 (5′-TGGGAGATGGGCGCGAGAAACTCCGTC-3′) 1000 gag [50]   smmgagR1 (5′-ATCAGCAGTGTCTGTGTCATCCAATT-3′)         smmgagF2 (5′-AGGGAAAAAAGCAGATGAATTAGAA–3′) 800       smmgagR2 (5′-GCTCTTGTAGAAYCTATCTACATA-3′)       smmenv (gp41) smmenvF1 (5′-GCTACGGCAGGTTCTGCAATGGG-3′) 650 env [50]   smmenvR1 (5′-CTGGTCCTTGCGGATATGGATCTG-3′)

        smmenvF2 (5′-GCTGTCCGCTCAGTCCCGGACTTT-3′) 490       smmenvR2 (5′-GGAGGAGAACACTGGCCTATA-3′)       Y = C/T, W = A/T, R = A/G, H AZD5582 in vitro = A/C/T, B = C/G/T, S = G/C, K = G/T, D = A/G/T, N = A/C/T/G Y = C/T, M = A/C, K = G Sequencing of any suspicious bands that appeared on subsequent gel electrophoresis was performed in buy Nutlin-3a both directions using the Sanger method, with all PCR products being sequenced on both strands. Sequences were compared to the public database using NCBI BLAST

[45]. Acknowledgements We thank the Ivorian authorities for their long-term support, especially the Ministry of Environment and Forests as well as the Ministry of Research, the directorship of the Taï National Park, the Office Ivoirien des Parcs et Réserves

and the Swiss Research Centre in Abidjan. We also thank S. Schenk, S. Metzger, and field assistants and students of the Taї Chimpanzee – and Taï Monkey Project for assistance in sample collection, and U. Thiesen, A. Blasse, A. Kopp, S. Handrick, J. Hinzmann and A. Hübner for assistance in the laboratory. Thiamet G For sequencing we thank J. Tesch. We thank A. Goffe for help with the manuscript. The study was funded by the Max-Planck-Institute for Evolutionary Anthropology, Leipzig, Germany and Robert Koch-Institut, Berlin, Germany, grant RO1 AI 50529 from the National Institute of Health, USA, and grant ANRS 12182 from the National Agency for AIDS Research (ANRS) in France. References 1. Keele BF, Van Heuverswyn F, Li Y, Bailes E, Takehisa J, Crenolanib Santiago ML, Bibollet-Ruche F, Chen Y, Wain LV, Liegeois F, et al.: Chimpanzee reservoirs of pandemic and nonpandemic HIV-1. Science 2006, 313:523–526.PubMedCrossRef 2. Hahn BH, Shaw GM, De Cock KM, Sharp PM: AIDS as a zoonosis: scientific and public health implications. Science 2000, 287:607–614.

J Raman Spectrosc 2011, 42:12–20 CrossRef 31 Chung AJ, Huh YS, E

J Raman Spectrosc 2011, 42:12–20.CrossRef 31. Chung AJ, Huh YS, Erickson D: Large area flexible SERS active substrates using engineered click here nanostructures. Nanoscale 2011, 3:2903–2908.CrossRef 32. Dickey MD, Weiss EA, Smythe EJ, Chiechi RC, Capasso F, Whitesides GM: Fabrication of arrays of metal and metal oxide nanotubes by shadow evaporation. ACS Nano 2008, 2:800–808.CrossRef 33. Giallongo G, Durante C, Pilot R, Garoli D, Bozio R, Romanato F, Gennaro A, Rizzi GA, Granozzi G: Growth and optical properties of silver nanostructures obtained on connected anodic aluminum oxide templates. Nanotechnology 2012, 23:325604.CrossRef 34. Huang C-H, Lin H-Y, Chen S, Liu C-Y, Chui H-C, Tzeng

Y: Electrochemically fabricated self-aligned 2-D silver/alumina arrays as reliable SERS

sensors. Opt Express 2011, 19:11441–11450.CrossRef 35. Huang Z, Meng G, Huang Q, Chen B, Zhu C, Zhang Z: Large-area Ag nanorod array substrates for SERS: AAO template-assisted fabrication, functionalization, and application in detection PCBs. J Raman Spectrosc 2013, 44:240–246.CrossRef 36. Ruan C, Eres G, Wang W, Zhang Z, Gu B: Controlled fabrication of nanopillar arrays as active substrates for surface-enhanced Raman spectroscopy. Langmuir 2007, 23:5757–5760.CrossRef 37. check details Prokes SM, Alexson DA, Glembocki OJ, Park HD, Rendell RW: Effect of crossing geometry on the plasmonic behavior of dielectric core/metal sheath nanowires. Appl Phys Lett 2009, 94:093105.CrossRef 38. Prokes SM, Glembocki OJ, Rendell RW, Ancona MG: Enhanced plasmon coupling in crossed dielectric/metal CX-5461 research buy nanowire composite geometries and applications to surface-enhanced Raman spectroscopy. Appl Phys Lett 2007, 90:093105.CrossRef 39. Tao A, Kim F, Hess C, Goldberger J, He RR, Sun YG, Xia YN, Yang PD: Langmuir-Blodgett silver nanowire monolayers for molecular sensing using surface-enhanced Raman spectroscopy. Nano Lett 2003, 3:1229–1233.CrossRef 40. Tian

C, Ding C, Liu S, Yang S, Song X, Ding B, Li Z, Fang J: Nanoparticle attachment on Protein kinase N1 silver corrugated-wire nanoantenna for large increases of surface-enhanced Raman scattering. ACS Nano 2011, 5:9442–9449.CrossRef 41. Feng M, Zhang M, Song J-M, Li X-G, Yu S-H: Ultralong silver trimolybdate nanowires: synthesis, phase transformation, stability, and their photocatalytic, optical, and electrical properties. ACS Nano 2011, 5:6726–6735.CrossRef 42. Qi J, Li Y, Yang M, Wu Q, Chen Z, Wang W, Lu W, Yu X, Xu J, Sun Q: Large-area high-performance SERS substrates with deep controllable sub-10-nm gap structure fabricated by depositing Au film on the cicada wing. Nanoscale Res Lett 2013, 8:437.CrossRef Competing interests The authors declare that they have no competing interests. Authors’ contributions QJ conceived of the study, carried out the fabrication of the SERS substrates, the measurement and analysis, the simulation, and drafted the manuscript. LY (Yudong) participated in the SERS spectra analysis and discussion.

J Med Microbiol 2003, 52:441–442 PubMedCrossRef 14 Meyer ME, Mor

J Med Microbiol 2003, 52:441–442.PubMedCrossRef 14. Meyer ME, Morgan WJB: Metabolic characterization of Brucella strains that show conflicting identity

by biochemical and serological methods. Bull World Alpelisib clinical trial Health Organ 1962, 26:823–827.PubMed 15. Cameron HS, Meyer ME: Metabolic studies on Brucella neotomae (Stoenner and Lackman). J Bacteriol 1958, 76:546–548.PubMed 16. Wundt W: Stoffwechseluntersuchungen als experimentelle Grundlage zur Einteilung des Genus Brucella . Zentralbl Bakteriol Orig 1963, 189:389–404.PubMed 17. Meyer ME: Metabolic characterization of the genus Brucella . III. Oxidative metabolism of strains that show anomalous characteristics by conventional determinative methods. J Bacteriol 1961, 82:401–410.PubMed 18. Meyer ME: Metabolic characterization of the genus Brucella . IV. Correlation of oxidative metabolic patterns and susceptibility to Brucella bacteriophage, type abortus , strain 3. J Bacteriol 1961, 82:950–953.PubMed 19. Meyer ME: Metabolic and bacteriophage identification of Brucella strains described as Brucella melitensis from cattle. Bull World Health Organ 1962, 26:829–831.PubMed 20. Jahans KL, Foster G, Broughton ES: The characterization Selleck YM155 of Brucella strains isolated from marine mammals. Vet Microbiol 1997, 57:373–382.PubMedCrossRef 21. Jensen AE, Ewalt DR, Cheville NF, Thoen CO, Payeur JB: Determination of stability of Brucella abortus RB51 by use of genomic fingerprint, oxidative

metabolism, and colonial morphology and differentiation of strain RB51 from B. abortus isolates from bison and elk. J Clin Microbiol 1996, 34:628–633.PubMed 22. Meyer ME: Inter- and intra-strain variants in the genus Brucella . Develop Biol Standard 1984, 56:73–83. 23. Meyer ME, Cameron HS: Metabolic characterization of the genus Brucella . I. Statistical evaluation of the oxidative rates by which type I of each species can be identified. J Bacteriol 1961, 82:387–395.PubMed 24. Meyer ME, Janus kinase (JAK) Cameron HS: Metabolic characterization of the genus Brucella . II. Oxidative metabolic patterns of the described biotypes. J Bacteriol 1961, 82:396–400.PubMed 25. Verger

JM, Grayon M: Oxidative metabolic profiles of Brucella species. Ann Sclavo 1977, 19:45–60. 26. Maquart M, Le Flèche P, Foster G, Tryland M, Ramisse F, Djønne B, Al Dahouk S, Jacques I, Neubauer H, Walravens K, Godfroid J, Cloeckaert A, Vergnaud G: MLVA-16 typing of 295 marine mammal Brucella isolates from this website different animal and geographic origins identifies 5 major groups within Brucella ceti and Brucella pinnipedialis . BMC Microbiol 2009, 9:145.PubMedCrossRef 27. Al Dahouk S, Le Flèche P, Nöckler K, Jacques I, Grayon M, Scholz HC, Tomaso H, Vergnaud G, Neubauer H: Evaluation of Brucella MLVA typing for human brucellosis. J Microbiol Methods 2007, 69:137–145.PubMedCrossRef 28. Ewalt DR, Payeur JB, Martin BM, Cummins DR, Miller WG: Characteristics of a Brucella species from a bottlenose dolphin ( Tursiops truncates ). J Vet Diagn Invest 1994, 6:448–452.PubMed 29.